Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11864-022-01034-3.pdf
Reference36 articles.
1. • Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med [Internet]. 2020 Sep; Available from: https://doi.org/10.1056/NEJMoa2027071. This reference is of importance because this phase III trial demonstrated a significant disease-free survival benefit of osimertinib over placebo in resected EGFR-mutated NSCLC, consequently leading to the approval of adjuvant osimertinib.
2. •• Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet. 2021;398(10308):1344–57 This reference is of outstanding importance because this is the first phase III trial to demonstrate a significant disease-free survival benefit of adjuvant immunotherapy in resected NSCLC, consequently leading to the approval of adjuvant atezolizumab.
3. Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for advanced non–small cell lung cancer: a decade of progress. Am Soc Clin Oncol Educ Book. 2021;41:e105–27.
4. • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50 This reference is of importance because this phase III trial demonstrated a significant overall survival benefit of consolidation durvalumab post-chemoradiation in unresectable stage 3 NSCLC, consequently introducing immunotherapy to the curative setting.
5. Liu L, Bai H, Wang C, Seery S, Wang Z, Duan J, et al. Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis. J Thorac Oncol. 2021;16(7):1099–117.
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer;Vaccines;2023-12-07
2. Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study;International Journal of Surgery;2023-09-26
3. The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer;Translational Lung Cancer Research;2023-09
4. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges;Journal of Thoracic Oncology;2023-09
5. Immunotherapy for early-stage non-small cell lung cancer: A system review;Journal of Cancer Research and Therapeutics;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3